- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05160103
16-Week Randomized Split-Face Efficacy Study of Cosmetic Formulations in Photoaged Pigmented Skin Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single site, double-blind randomized, split face, efficacy study. All subjects will receive a cleanser, Day Cream/sunscreen, and two treatment products. The treatment products will be applied in a split face fashion including behind the ear.
Local volunteer subjects will be enrolled such that a total of eighty-four (84) subjects will complete the study; with 24 subjects completing in each treatment.
Each subject will receive a cleanser, Day Cream/sunscreen and two treatment products as per the randomization. Subjects will use the cleanser twice daily, Day Cream/sunscreen in the morning, and the treatment products as specified after cleansing in the evening, for a period of 16 weeks. Clinical assessments, non-invasive instrument measurements and photographs will be completed at baseline and weeks 4, 8, 12, and 16. Biopsies will be taken at baseline and Week 16.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Musonda Machona, MD
- Phone Number: +27(0)634328862
- Email: musondamachona@gmail.com
Study Contact Backup
- Name: Nonhlanhla P Khumalo, PhD
- Phone Number: +27(0)214043376
- Email: n.khumalo@uct.ac.za
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be a female in general good health, based on medical history reported by the subject;
- From thirty (30) to sixty-five (65) years of age, inclusive;
- Fitzpatrick skin types IV, V or VI;
- Have mild to moderate skin tone evenness (a score of 3-6);
- Willing to avoid excessive solar or UV exposure including: minimizing direct sun exposure and avoiding tanning beds and sunless tanning products for the duration of the study;
- Willing to cleanse the face and remove all facial and all eye make-up prior to (or upon arrival) every study visit;
- Willing to use no other topical products on the face for the duration of the study except the assigned test product and the subject's regular brand(s) of non-medicated make-up products that do not contain salicylic acid, benzoyl peroxide, AHA's, retinol, or their analogs or derivatives;
- Willing to refrain from using exfoliating products for the duration of the study;
- Not make any changes to her usual skin care regimen while participating in this study, other than those required by the study protocol;
- Willing and able to follow all study instructions and adhere to study restrictions;
- Read and sign an IRB approved informed consent form after the nature of the study has been fully explained and all questions have been answered by site staff;
- Female subjects determined to be of child-bearing potential must indicate that they are not pregnant and/or lactating, nor do they intend to become pregnant during their study participation;
- Female subjects determined to be of child-bearing potential must agree to practice a medically acceptable form of birth control during the study;
Medically acceptable forms of birth control that may be used by the subject and/or his/her partner include:
- Established use of hormonal methods of contraception (oral, injected, implanted, patch or vaginal ring)
- Barrier methods of contraception (condom or diaphragm)
- Intrauterine device or system (IUD/IUS)
- Surgical sterilization (vasectomy, hysterectomy, tubal occlusion, uterine ablation)
- Abstinence from heterosexual intercourse, when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence is not an acceptable method of contraception
Exclusion Criteria:
- Has participated in any other clinical facial use study within four (4) weeks from the start of the study;
- Has received any type of skin treatment or procedure in the past 3 (3) months including: chemical peels, microdermabrasion, injection of collagen or other filler, Botox® injections, or any treatment involving heat, light, or RF energy;
- Is currently under a physician's care for a medical problem that, in the opinion of the Investigator or his designee, could affect the subject's treatment response;
- Is nursing, pregnant, or planning a pregnancy during the course of this study;
- Has excessive facial hair, or scars which could interfere with study evaluation in the opinion of the Investigator;
- Is taking any prescription or over-the-counter medication that, in the opinion of the Investigator or his designee, could affect the subject's treatment response;
- Has any other condition that, in the opinion of the Investigator or his designee, could interfere with the subject's ability to use the treatment as instructed, alter treatment response, or affect their ability to complete the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Tone Unevenness
Time Frame: Every 4 weeks up to 16 weeks
|
Using a 0-9 scale where 0= even tone and 9=severe blotchy hyperpigmentation.
Subjects will be recruited with mild to moderate skin tone unevenness.
The goal is to show improvements by dermatologist assessments and photography
|
Every 4 weeks up to 16 weeks
|
|
Skin Firming
Time Frame: Every 4 weeks up to 16 weeks
|
Using a non-invasive clinical instrument (Cutometer) skin elasticity will be measure of the facial cheek
|
Every 4 weeks up to 16 weeks
|
|
Skin Moisture
Time Frame: Every 4 weeks up to 16 weeks
|
Using a non-invasive clinical instrument (SkiCon) skin conductance will be measure of the facial cheek
|
Every 4 weeks up to 16 weeks
|
|
Skin Oiliness
Time Frame: Every 4 weeks up to 16 weeks
|
Using a non-invasive clinical instrument (Sebumeter) skin conductance will be measure of the facial cheek
|
Every 4 weeks up to 16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ardeshir Bayat, PhD, Professor & Co-Director, University of Cape Town
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging Problems
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
University of Santiago de CompostelaState Research Agency, SpainCompleted
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Seoul National University Bundang HospitalCompleted
-
University of MichiganTerminated
-
University of ValenciaCompletedAging ProblemsSpain
-
University of ValenciaCompletedAging ProblemsSpain
-
University of ValenciaUnknownAging ProblemsSpain
-
University of ValenciaTerminated
Clinical Trials on Cosmetic Formulations
-
Unilever R&DMS Clinical Research Pvt. LtdNot yet recruiting
-
BiosynNational Institute of Allergy and Infectious Diseases (NIAID)UnknownHIV InfectionsUnited States
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAtopic DermatitisChina
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes MellitusUnited States
-
Pierre Fabre Dermo CosmetiqueCompleted
-
Ningbo No. 1 HospitalUnknownBowel PreparationChina
-
SVR GroupCompletedAtopic DermatitisBelgium
-
Superior UniversityCompletedCosmetic Product Causing Toxic EffectPakistan
-
Johnson & Johnson Consumer Inc. (J&JCI)University of SheffieldTerminated
-
Pierre Fabre Dermo CosmetiqueCompleted